Detail akcie ProQR Therapeutics online

Business Summary: ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Financial Summary: BRIEF: For the three months ended 31 March 2026, ProQR Therapeutics NV revenues decreased 57% to EUR2M. Net loss increased 33% to EUR13.4M. Revenues reflect Revenue decrease of 55% to EUR2M, Other Income decrease from EUR222K to EUR0K. Higher net loss reflects RNA based Therapeutics segment loss increase of 26% to EUR13.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.10 to -EUR0.13.